A Phase 3, Double-Blind, Randomized Trial Evaluating the Efficacy and Safety of Elritercept (TAK‑226) Compared to Placebo in Participants With Myelofibrosis and Anemia on Concurrent Ruxolitinib Therapy

Inside our bones is spongy tissue called bone marrow, which produces healthy blood cells. In myelofibrosis, the bone marrow becomes scarred and cannot make enough red blood cells. Red blood cells carry oxygen around the body, so having too few of them (a condition called anaemia) leaves people feeling exhausted, weak, and short of breath. Many patients need regular blood transfusions at the hospital to top up their blood levels.

Many people with myelofibrosis take a standard tablet called ruxolitinib (Jakavi) to ease symptoms like an enlarged spleen, night sweats, and bone pain. While ruxolitinib is helpful, it does not always fix anaemia and can sometimes make it worse. This clinical trial is testing whether adding an investigational drug called elritercept can help the body produce more red blood cells on its own.

This is a Phase 3 study, which means it tests the medicine in a larger group of people to confirm how well it works. Half of the participants will receive elritercept, and the other half will receive a placebo (an inactive dummy treatment). Both groups will continue taking their regular ruxolitinib tablets. To keep the test fair, neither you nor your doctor will know which treatment you are receiving until the trial is complete.

The findings from this study could be very important. If elritercept works, it could help people with myelofibrosis depend less on hospital blood transfusions, giving them more energy and independence in their daily lives.